Abstract
Abstract As long as there is no consensus on the definition, diagnostic criteria, and pathogenesis of left ventricular hypertrabeculation (LVHT)/noncompaction misdiagnosis, overreaction, and mistreatment of this abnormality will eventually continue. When considering a therapy for patients presenting with LVHT it has to be taken into account that LVHT is not associated with an increased risk of thrombo-embolism in the absence of atrial fibrillation or systolic dysfunction. There is also no proof that the degree of LVHT correlates with the degree of systolic dysfunction. Secondary prevention of stroke/embolism and sudden cardiac death is indicated in LVHT only if cardiac investigations reveal atrial fibrillation, systolic dysfunction, or ventricular arrhythmias. Up to what we know at the moment LVHT patients should be closely monitored by conventional cardiologic and neurologic diagnostic tools and appropriate measures taken, only if indicated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
